E. Campo and S. Rule, Mantle cell lymphoma: evolving management strategies, Blood, vol.125, issue.1, pp.48-55, 2015.
DOI : 10.1182/blood-2014-05-521898

URL : http://www.bloodjournal.org/content/bloodjournal/125/1/48.full.pdf

S. Bè-a, R. Valdésvald´valdés-mas, and A. Navarro, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences, vol.110, issue.4, pp.18250-18255, 2013.
DOI : 10.1073/pnas.1205299110

R. Hendriks, S. Yuvaraj, and L. Kil, Targeting Bruton's tyrosine kinase in B cell malignancies, Nature Reviews Cancer, vol.64, issue.4, pp.219-232, 2014.
DOI : 10.1124/dmd.111.040840

M. Wang, S. Rule, and P. Martin, Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, New England Journal of Medicine, vol.369, issue.6, pp.507-516, 2013.
DOI : 10.1056/NEJMoa1306220

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941/pdf

R. Rahal, M. Frick, and R. Romero, Pharmacological and genomic profiling identifies NF-??B???targeted treatment strategies for mantle cell lymphoma, Nature Medicine, vol.1, issue.1, pp.87-92, 2014.
DOI : 10.1093/bib/bbs017

D. Chiron, D. Liberto, M. Martin, and P. , Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma, Cancer Discovery, vol.4, issue.9, pp.1022-1035, 2014.
DOI : 10.1158/2159-8290.CD-14-0098

D. Chiron, C. Dousset, and C. Brosseau, Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015.
DOI : 10.18632/oncotarget.3275

J. Seymour, J. Gerecitano, and B. Kahl, The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients [abstract], Blood, vol.122, issue.21, 2013.

D. Chiron, C. Bellanger, and A. Papin, Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma, Blood, vol.128, issue.24, pp.2808-2818, 2016.
DOI : 10.1182/blood-2016-06-720490

P. Masiakowski and R. Carroll, A novel family of cell surface receptors with tyrosine kinase-like domain, J Biol Chem, vol.267, issue.36, pp.26181-26190, 1992.

J. Green, S. Kuntz, and P. Sternberg, Ror receptor tyrosine kinases: orphans no more, Trends in Cell Biology, vol.18, issue.11, pp.536-544, 2008.
DOI : 10.1016/j.tcb.2008.08.006

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672995/pdf

J. Murphy, Q. Zhang, and S. Young, A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties, Biochemical Journal, vol.13, issue.2, pp.323-334, 2014.
DOI : 10.1074/mcp.M800588-MCP200

J. Mendrola, F. Shi, J. Park, and M. Lemmon, Receptor tyrosine kinases with intracellular pseudokinase domains, Biochemical Society Transactions, vol.13, issue.4, pp.1029-1036, 2013.
DOI : 10.1074/jbc.M207135200

URL : http://www.biochemsoctrans.org/content/ppbiost/41/4/1029.full.pdf

I. Oishi, S. Takeuchi, and R. Hashimoto, Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system, Genes to Cells, vol.5, issue.1, pp.41-56, 1999.
DOI : 10.1126/science.274.5290.1123

N. Borcherding, D. Kusner, G. Liu, and W. Zhang, ROR1, an embryonic protein with an emerging role in cancer biology, Protein & Cell, vol.181, issue.7, pp.496-502, 2014.
DOI : 10.1016/j.ajpath.2012.08.024

M. Asem, S. Buechler, R. Wates, D. Miller, and M. Stack, Wnt5a Signaling in Cancer, Cancers, vol.21, issue.9, 2016.
DOI : 10.1198/016214504000000683

URL : http://www.mdpi.com/2072-6694/8/9/79/pdf

M. Katoh and M. Katoh, Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades, Int J Mol Med, vol.23, issue.6, pp.763-769, 2009.

D. Naskar, G. Maiti, A. Chakraborty, A. Roy, D. Chattopadhyay et al., Wnt5a-Rac1-NF-??B Homeostatic Circuitry Sustains Innate Immune Functions in Macrophages, The Journal of Immunology, vol.192, issue.9, pp.4386-4397, 2014.
DOI : 10.4049/jimmunol.1302817

URL : http://www.jimmunol.org/content/jimmunol/192/9/4386.full.pdf

J. Yu, L. Chen, and B. Cui, Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation, Journal of Clinical Investigation, vol.126, issue.2, pp.585-598, 2016.
DOI : 10.1172/JCI83535DS1

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731190/pdf

B. Cui, E. Ghia, and L. Chen, High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia, Blood, vol.128, issue.25, pp.2931-2940, 2016.
DOI : 10.1182/blood-2016-04-712562

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179332/pdf

V. Bicocca, B. Chang, and B. Masouleh, Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia, Cancer Cell, vol.22, issue.5, pp.656-667, 2012.
DOI : 10.1016/j.ccr.2012.08.027

A. Choudhury, K. Derkow, and A. Daneshmanesh, Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells, British Journal of Haematology, vol.23, issue.Pt 2, pp.327-335, 2010.
DOI : 10.1016/S0002-9440(10)64555-5

A. Daneshmanesh, M. Hojjat-farsangi, and A. Khan, Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells, Leukemia, vol.177, issue.6, pp.1348-1355, 2012.
DOI : 10.1371/journal.pone.0021018

M. Choi, G. Widhopf, . Ii, and C. Wu, Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1, Clinical Lymphoma Myeloma and Leukemia, vol.15, pp.167-169, 2015.
DOI : 10.1016/j.clml.2015.02.010

J. Yu, L. Chen, and B. Cui, Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib, Leukemia, vol.7, issue.6, pp.1333-1339, 2017.
DOI : 10.1056/NEJMoa1509981

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462858/pdf

M. Hanf, D. Chiron, and S. De-visme, The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma, BMC Cancer, vol.94, issue.1, p.802, 2016.
DOI : 10.1038/labinvest.2014.61

URL : https://hal.archives-ouvertes.fr/hal-01524145

J. Hiraga, A. Tomita, and T. Sugimoto, Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance, Blood, vol.113, issue.20, pp.4885-4893, 2009.
DOI : 10.1182/blood-2008-08-175208

T. Fukuda, L. Chen, and T. Endo, Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a, Proceedings of the National Academy of Sciences, vol.195, issue.1, pp.3047-3052, 2008.
DOI : 10.1006/cimm.1999.1513

K. Kamizaki, R. Doi, and M. Hayashi, The Ror1 receptor tyrosine kinase plays a critical role in regulating satellite cell proliferation during regeneration of injured muscle, Journal of Biological Chemistry, vol.12, issue.38, pp.15939-15951, 2017.
DOI : 10.1038/nature08209

S. Baskar, A. Wiestner, W. Wilson, I. Pastan, and C. Rader, Targeting malignant B cells with an immunotoxin against ROR1, mAbs, vol.141, issue.3, pp.349-361, 2012.
DOI : 10.1073/pnas.1102746108

URL : http://www.tandfonline.com/doi/pdf/10.4161/mabs.19870?needAccess=true

P. Janovska, L. Poppova, and K. Plevova, Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia, Clinical Cancer Research, vol.22, issue.2, pp.459-469, 2016.
DOI : 10.1158/1078-0432.CCR-15-0154

T. Pemovska, M. Kontro, and B. Yadav, Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia, Cancer Discovery, vol.3, issue.12, pp.1416-1429, 2013.
DOI : 10.1158/2159-8290.CD-13-0350

URL : http://cancerdiscovery.aacrjournals.org/content/candisc/3/12/1416.full.pdf

Y. Li, M. Bouchlaka, and J. Wolff, FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma, Oncogene, vol.28, issue.48, pp.6223-6234, 2016.
DOI : 10.1038/leu.2014.91

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102814/pdf

G. Barna, R. Mihalik, and B. Timártim´timár, ROR1 expression is not a unique marker of CLL, Hematological Oncology, vol.82, issue.3, pp.17-21, 2011.
DOI : 10.1189/jlb.0307194

M. Davids and A. Letai, ABT-199: Taking Dead Aim at BCL-2, Cancer Cell, vol.23, issue.2, pp.139-141, 2013.
DOI : 10.1016/j.ccr.2013.01.018

URL : https://doi.org/10.1016/j.ccr.2013.01.018